Penumbra Inc. ((PEN)) has held its Q3 earnings call. Read on for the main highlights of the call.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Penumbra Inc.’s recent earnings call painted a picture of robust growth and strategic advancements, marked by significant revenue increases and promising clinical trial results. However, the company also faces challenges in international markets and rising operational costs.
Strong Revenue Growth
Penumbra Inc. reported a total revenue of $354.7 million, marking a year-over-year growth of 17.8% on a reported basis and 16.9% in constant currency. The U.S. market was a significant contributor, with revenue growing by 21.5% to $275 million, showcasing the company’s strong domestic performance.
VTE Franchise Leading Growth
The VTE franchise emerged as a key driver of Penumbra’s corporate growth, delivering an impressive 34% year-over-year increase. This segment’s robust performance underscores its strategic importance to the company’s overall growth trajectory.
Embolization and Access Revenue Surge
In the U.S., embolization and access revenue surged by 29.2% year-over-year, reaching $83 million. This growth highlights the increasing demand and successful market penetration of Penumbra’s embolization products.
Gross Margin Expansion
Penumbra’s gross margin improved to 67.8%, up 130 basis points from the previous year. The company is optimistic about further margin expansion, with expectations to exceed 70% by the end of 2026.
Positive Feedback for STORM-PE Trial
The STORM-PE trial results demonstrated the superiority of CAVT in reducing right heart strain in PE patients, coupled with a favorable safety profile. This has garnered positive feedback from the medical community, reinforcing the potential of Penumbra’s clinical innovations.
Raising Revenue Guidance
Penumbra has raised its revenue guidance for the year to between $1.375 billion and $1.380 billion. This upward revision reflects the company’s confidence in its growth strategy and market positioning.
China Growth Headwinds
Despite facing growth headwinds in China, Penumbra’s international revenue still increased by 6.6% year-over-year. This indicates resilience in the company’s global operations amidst challenging market conditions.
Slight Decline in U.S. Stroke Market
The U.S. stroke market experienced a slight decline, yet Penumbra managed to gain market share. This demonstrates the company’s competitive edge and ability to navigate market fluctuations effectively.
Operating Expenses Increase
Operating expenses rose to $191.6 million, or 54% of revenue, up from $160 million. This increase is attributed to strategic investments in expanding the sales force, which is expected to support future growth.
Forward-Looking Guidance
Penumbra has set a positive outlook for the future, with a revenue guidance increase to $1.375 billion to $1.380 billion. The company anticipates U.S. thrombectomy growth of 20% to 21% for 2025, driven by innovative products like the Lightning Bolt 16 and Lightning Flash 3.0, which have received FDA clearance.
In conclusion, Penumbra Inc.’s earnings call highlighted a strong performance with significant revenue growth and strategic advancements, particularly in the VTE and embolization segments. Despite challenges in international markets and increased operational costs, the company remains optimistic about its future prospects, as reflected in its raised revenue guidance and focus on innovative product development.